Neurocrine Bioscience diskutieren
Neurocrine Bioscience
WKN: 900964 / Symbol: NBIX / Name: Neurocrine / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
130,15 €
-0,83 %
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at HC Wainwright from $190.00 to $185.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Bank of America Co. from $184.00 to $179.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Wedbush from $157.00 to $147.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Guggenheim from $165.00 to $163.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $185.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $150.00 price target on the stock, down previously from $185.00.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at JPMorgan Chase & Co. from $183.00 to $184.00. They now have an "overweight" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at UBS Group AG from $154.00 to $137.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $137.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $138.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at HC Wainwright from $185.00 to $168.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Evercore ISI from $190.00 to $185.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Needham & Company LLC from $138.00 to $139.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at UBS Group AG from $137.00 to $152.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Guggenheim from $155.00 to $165.00. They now have a "buy" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target raised by analysts at Royal Bank of Canada from $137.00 to $145.00. They now have an "outperform" rating on the stock.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $154.00 price target on the stock, down previously from $160.00.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Wedbush.
Ratings data for NBIX provided by MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $145.00 price target on the stock.
Ratings data for NBIX provided by MarketBeat
Neueste Beiträge
Wells_Fargo___Compan in Johnson & Johnson diskutieren